한글목차

돼지 백신 시장 규모는 2025년 22억 8,000만 달러에서 2034년에는 36억 9,000만 달러에 달할 것으로 예측되고 있으며, 2026-2034년에 CAGR 5.49%로 성장이 전망됩니다.

돼지 백신 시장은 돼지 떼에 영향을 미치는 전염병의 확산 증가에 힘입어 견고한 성장이 예상됩니다. 전 세계에서 돼지고기에 대한 수요가 지속적으로 증가함에 따라 양돈장의 건강과 생산성을 보장하기 위한 효과적인 백신 접종 전략의 필요성이 매우 중요해지고 있습니다. 새로운 병원체의 출현과 통제되었던 질병의 재유행으로 인해 백신 제제의 지속적인 연구개발이 요구되고 있습니다. 각 업체들은 재조합 백신, mRNA 기반 솔루션 등 효과와 안전성을 향상시킬 수 있는 혁신적인 기술에 많은 투자를 하고 있으며, 이를 통해 양돈업자들이 직면한 진화하는 도전에 대응하고 있습니다.

또한 축산 농가의 바이오 보안 대책에 대한 인식이 높아지면서 돼지 백신 시장에 큰 영향을 미치고 있습니다. 생산자들은 종합적인 사양관리 전략의 중요한 요소로서 백신 접종의 중요성을 점점 더 많이 인식하고 있습니다. 이러한 인식의 변화는 질병 예방에 대한 적극적인 노력을 촉진하고, 결과적으로 백신 접종률 향상과 더 튼튼한 돈군 형성에 기여하고 있습니다. 백신 접종 일정을 모니터링하고 관리하는 디지털 툴을 통합하는 움직임도 확산되고 있으며, 농가는 가축의 헬스케어 방법을 최적화하고 전체 생산성을 향상시킬 수 있습니다.

또한 신흥 시장을 중심으로 한 세계 양돈 산업의 확대는 양돈 백신 시장에 수익성 높은 기회를 제공합니다. 각국이 소비자 수요 증가에 대응하기 위해 축산 역량을 강화하는 가운데, 첨단화된 백신 접종 프로그램 도입이 필수적입니다. 백신 제조업체와 농업 조직과의 협력을 통해 이들 지역의 기술 이전을 촉진하고 백신 기술에 대한 접근성을 향상시킬 수 있을 것으로 기대됩니다. 돼지 백신 시장 전망은 지속적인 기술 혁신, 질병 관리에 대한 의식의 향상, 동물의 건강과 복지 향상을 위한 노력으로 특징지어지며 유망한 전망을 보여주고 있습니다.

목차

제1장 서론

제2장 개요

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 돼지 백신 시장 : 제품별

제5장 세계의 돼지 백신 시장 : 질환 유형별

제6장 세계의 돼지 백신 시장 : 최종사용자별

제7장 세계의 돼지 백신 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

영문목차

The Swine Vaccines Market size is expected to reach USD 3.69 Billion in 2034 from USD 2.28 Billion (2025) growing at a CAGR of 5.49% during 2026-2034.

The swine vaccines market is set for robust growth, driven by the increasing prevalence of infectious diseases affecting pig populations. As the global demand for pork continues to rise, the need for effective vaccination strategies to ensure herd health and productivity becomes paramount. The emergence of novel pathogens and the resurgence of previously controlled diseases necessitate ongoing research and development in vaccine formulations. Companies are investing heavily in innovative technologies, such as recombinant vaccines and mRNA-based solutions, which promise enhanced efficacy and safety profiles, thereby addressing the evolving challenges faced by swine producers.

Moreover, the growing awareness of biosecurity measures among livestock farmers is significantly influencing the swine vaccines market. Producers are increasingly recognizing the importance of vaccination as a critical component of comprehensive herd management strategies. This shift in mindset is fostering a proactive approach to disease prevention, leading to higher vaccination rates and, consequently, a more resilient swine population. The integration of digital tools for monitoring and managing vaccination schedules is also gaining traction, enabling farmers to optimize their herd health management practices and improve overall productivity.

Additionally, the expansion of the global swine industry, particularly in emerging markets, presents lucrative opportunities for the swine vaccines market. As countries strive to enhance their livestock production capabilities to meet growing consumer demand, the adoption of advanced vaccination programs becomes essential. Collaborations between vaccine manufacturers and agricultural organizations are expected to facilitate knowledge transfer and improve access to vaccination technologies in these regions. The future of the swine vaccines market appears promising, characterized by continuous innovation, increased awareness of disease management, and a commitment to enhancing animal health and welfare.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Inactivated vaccines
• Live attenuated vaccines
• Recombinant vaccines
• Subunit vaccines
• Toxoid vaccines
• Other products

By Disease Type

• Porcine reproductive and respiratory syndrome (PRRS)
• Porcine circovirus type 2 (PCV2)
• Mycoplasma hyopneumoniae
• Classical swine fever (CSF)
• Swine influenza
• Erysipelas
• Foot-and-Mouth disease (FMD)
• African swine fever (ASF)
• Porcine parvovirus
• Other disease types

By End-user

• Veterinary hospitals & clinics
• Swine farms
• Research institutes

COMPANIES PROFILED

• Biogenesis Bago, Bioveta, Boehringer Ingelheim International GmbH, Ceva Sant Animale, Elanco Animal Health Incorporated, HIPRA, Indian Immunologicals Limited, Merck Co Inc, Phibro Animal Health Corporation, Vaxxinova, Virbac, Zoetis Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL SWINE VACCINES MARKET: BY PRODUCT 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Inactivated vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Live attenuated vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Recombinant vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.5. Subunit vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.6. Toxoid vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.7. Other products Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL SWINE VACCINES MARKET: BY DISEASE TYPE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Porcine reproductive and respiratory syndrome (PRRS) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Porcine circovirus type 2 (PCV2) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Mycoplasma hyopneumoniae Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Classical swine fever (CSF) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.6. Swine influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.7. Erysipelas Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.8. Foot-and-Mouth disease (FMD) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.9. African swine fever (ASF) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.10. Porcine parvovirus Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.11. Other disease types Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL SWINE VACCINES MARKET: BY END-USER 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Veterinary hospitals & clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Swine farms Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Research institutes Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL SWINE VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Product
  • 7.2.2 By Disease Type
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Product
  • 7.3.2 By Disease Type
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Product
  • 7.4.2 By Disease Type
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Product
  • 7.5.2 By Disease Type
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Product
  • 7.6.2 By Disease Type
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SWINE VACCINES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Biogenesis Bago
  • 9.2.2 Bioveta
  • 9.2.3 Boehringer Ingelheim International GmbH
  • 9.2.4 Ceva SantAfA(C) Animale
  • 9.2.5 Elanco Animal Health Incorporated
  • 9.2.6 HIPRA
  • 9.2.7 Indian Immunologicals Limited
  • 9.2.8 Merck & Co. Inc
  • 9.2.9 Phibro Animal Health Corporation
  • 9.2.10 Vaxxinova
  • 9.2.11 Virbac
  • 9.2.12 Zoetis Inc